Table 2 Application of proposed method to the determination of the studied drugs in their dosage forms.
Preparation | Proposed method | Reference method[4] | |||
|---|---|---|---|---|---|
Conc. added (μg/mL) | Conc. found (μg/mL) | Recovery (%) | Conc.added (μg/mL) | Recovery(%) | |
Sirdalud ® tablets | 2.0 | 2.02 | 101.00 | 40.0 | 99.40 |
(2 mg tizanidine hydrochloride/tablet) | 4.0 | 3.98 | 99.50 | 80.0 | 100.50 |
8.0 | 8.03 | 100.37 | 100.0 | 100.60 | |
± SD | 100.29 ± 0.75 (found amount = 2.005 mg/tablet) | 100.20 ± 0.66 | |||
t | 0.21 (2.77) | ||||
F | 1.28 (19) | ||||
Sirdalud ® tablets | 2.0 | 2.03 | 101.5 | 40.0 | 99.90 |
(4 mg tizanidine hydrochloride/tablet) | 4.0 | 4.00 | 100.00 | 80.0 | 98.50 |
8.0 | 7.96 | 99.50 | 100.0 | 100.20 | |
± SD | 100.33 ± 1.04 (found amount = 4.013 mg/tablet) | 99.53 ± 0.91 | |||
t | 1.00 (2.77) | ||||
F | 1.31(19) | ||||
Norflex ® tablets (100 mg orphenadrine citrate/tablet) | 5.0 | 4.99 | 99.90 | 20.0 | 98.79 |
10.0 | 9.87 | 98.70 | 50.0 | 100.55 | |
12.0 | 12.11 | 100.90 | 100.0 | 98.99 | |
± SD | 99.83 ± 1.10 (found amount = 99.83 mg/tablet) | 99.44 ± 0.96 | |||
t | 0.46 (2.77) | ||||
F | 1.31 (19) | ||||
Norflex ® ampoules (30 mg orphenadrine citrate/mL) | 3.0 | 2.95 | 98.30 | 20.0 | 98.76 |
5.0 | 5.10 | 102.00 | 50.0 | 98.00 | |
10.0 | 10.07 | 100.70 | 100.0 | 100.30 | |
± SD | 100.33 ± 1.87 (found amount = 30.099 mg/mL) | 99.02 ± 1.17 | |||
t | 1.03 (2.77) | ||||
F | 2.56 (19) | ||||